Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Limited-Stage Small-Cell Lung Cancer (DeLLphi-306)
NCT06117774Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2024
- Primary completion
- Apr 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 27
01
Overview
A Phase 3 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Feb 2024; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06117774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117774.